Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Roxadustat - FibroGen

Next Previous
Drug Profile

Roxadustat - FibroGen

Alternative Names: ASP 1517; AZD 9941; Evrenzo; FG-4592

Latest Information Update: 26 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FibroGen
  • Developer Astellas Pharma; AstraZeneca; FibroGen
  • Class Amides; Antianaemics; Carboxylic acids; Isoquinolines; Small molecules
  • Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaemia
  • Phase II Chemotherapy-induced anaemia
  • Discontinued Sickle cell anaemia

Most Recent Events

  • 11 Nov 2019 Launched for Anaemia in China (PO)
  • 11 Nov 2019 Astellas Pharma announces intention to submit MAA to the EMA for Anaemia in the first quarter of 2020
  • 11 Nov 2019 FibroGen plans to submit regulatory filings to the authorities other than the US FDA and EMA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top